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Abstract Biosynthesis of heme A, a prosthetic group of
cytochrome oxidase (COX), involves an initial farnesylation of
heme B. The heme O product formed in this reaction is modified
by hydroxylation of the methyl group at carbon C-8 of the
porphyrin ring. This reaction was proposed to be catalyzed by
Cox15p, ferredoxin, and ferredoxin reductase. Oxidation of the
alcohol to the corresponding aldehyde yields heme A. In the
present study we have assayed heme A and heme O in yeast COX
mutants. The steady state concentrations of the two hemes in the
different strains studied indicate that hydroxylation of heme O,
catalyzed by Cox15p, is regulated either by a subunit or
assembly intermediate of COX. The heme profiles of the mutants
also suggest positive regulation of heme B farnesylation by the
hydroxylated intermediate formed at the subsequent step or by
Cox15p itself. ß 2002 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Heme A is an important electron carrier of mitochondrial
and some bacterial cytochrome oxidases (COXs). The synthe-
sis of heme A begins with farnesylation of a vinyl group at
carbon C-2 of the porphyrin ring of heme B (protoheme) by
the product of the COX10 gene. [1,2]. Conversion of the re-
sultant heme O to heme A requires a further oxidation of the
methyl group at C-8 to a formyl group [3]. We have previ-
ously proposed that the C-8 methyl is ¢rst hydroxylated by a
three-component monooxygenase consisting of Cox15p, ferre-
doxin (Yah1p), and ferredoxin reductase (Arh1p) [4]. Accord-
ing to this scheme the last step of the pathway involves oxi-
dation of the C-8 methanol group to a formyl group. The
enzyme responsible for this reaction has not been identi¢ed.
The requirement of Cox15p, Yah1p and Arh1p for heme A
synthesis is supported in part by studies on the heme compo-
sitions of mitochondria in di¡erent COX1 mutants [5]. In the
course of these studies, we noted that most COX mutants are
grossly de¢cient in heme A but accumulate variable amounts
of heme O. A notable exception are cox15 mutants as they
lack heme A altogether and have only negligible amounts of
heme O [4]. The failure of cox15 mutants to accumulate heme
O was unexpected in view of the proposed role of Cox15p in
hydroxylation of heme O. The generally low levels of heme A
in mutants completely blocked in COX assembly and the
equally low amount of heme O in cox15 mutants, suggested
that either conversion of heme B to heme A is regulated or
that hemes A and O are unstable when COX assembly is
blocked.
To examine the relationship of heme A to COX synthesis
we have extended the heme analyses to mutants with null
mutations in COX15 and other genes previously implicated
in COX assembly [6]. The heme compositions of the single
and double mutants and of mutants overexpressing COX10
[2] are most compatible with several regulatory steps in heme
A synthesis and are discussed in light of what is currently
know about this pathway.
2. Materials and methods
2.1. Yeast strains and media
The genotypes and sources of the Saccharomyces cerevisiae strains
used in this study are listed in Table 1. The compositions of YPD
(rich glucose), YEPG (rich glycerol), and YPGal (rich galactose) used
to grow yeast have been described elsewhere [15].
2.2. Construction of imp2 and pet117 null alleles
A null allele of IMP2 [16] was constructed by replacing the se-
quence between KpnI and MscI spanning most of the gene with a
1 kb fragment containing URA3. A clean deletion of PET117 [17]
was obtained by polymerase chain reaction (PCR) ampli¢cation of
the 5P- and 3P-non-coding regions with bi-directional primers. The
gene was replaced with a 1 kb fragment of DNA containing HIS3.
The null alleles, isolated as linear fragments of DNA, were substituted
for the native genes in W303-1A and W303-1B by the one-step gene
replacement method [18]
2.3. Heme analysis
Mitochondria were prepared from yeast grown in YPGal to early
stationary phase by the method of Faye et al. [19] using Zymolyase
20 000 (ICN, CA, USA) to convert cells to spheroplasts. The spher-
oplasts were suspended in 0.5 M sorbitol, 20 mM Tris^HCl, pH 7.5,
0.5 mM EDTA at a protein concentration of 20 mg/ml and hemes
were extracted by mixing 200 Wl of the mitochondrial suspension with
1 ml of acetone containing 3% HCl. The conditions for separation of
hemes on a 3.9U300 mm C18 Bondclone column (Phenomenex, CA,
USA) have been described [4]. Fluorescent porphyrin compounds
were monitored £uorometrically with an excitation wavelength of
400 nm and emission wavelength of 600 nm. The heme B standard
was purchased from Sigma (St. Louis, MO, USA). Heme A was
extracted from partially puri¢ed COX, and heme O from Escherichia
coli cells. The concentrations of heme were calculated from the inte-
grated areas under the peaks corresponding to hemes A, B and O.
Since the concentration of heme B was not signi¢cantly a¡ected in
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COX mutants, the heme A and heme O values were normalized to
heme B to correct for errors introduced by heme extraction and sam-
ple handling. The heme values reported in Figs. 3 and 4 were obtained
from a single analysis. Some mutants (imp2, sco1, cox11, cyc3, pet117,
pet111, shy1, cox15) were analyzed 2^3 times and the results obtained
were similar to those reported.
2.4. Miscellaneous procedures
Standard methods were used for the preparation and ligation of
DNA fragments and for transformation and recovery of plasmid
DNA from E. coli [20]. Yeast was transformed by the method of
Schiestl and Gietz [21]. Proteins were separated on a 12% polyacryl-
amide gel by sodium dodecyl sulfate^polyacrylamide gel electropho-
resis (SDS^PAGE) [22]. Western blots were treated with a monoclonal
antibody against yeast Cox1p (Molecular Probes, OR, USA) followed
by a second reaction with anti-mouse or anti-rabbit IgG conjugated to
horseradish peroxidase (Sigma, MO, USA). Antibody^antigen com-
plexes were visualized with the SuperSignal chemiluminescent sub-
strate kit (Pierce, IL, USA). Mitochondrial spectra were recorded
on deoxycholate extracts at room temperature [23]. Protein concen-
trations were determined by the method of Lowry et al. [24].
3. Results and discussion
3.1. COX mutants have depressed levels of heme A
S. cerevisiae mutants blocked in COX assembly have 30^
300 times less heme A than the parental respiratory competent
strain (Table 2). The exceptions are shy1, cox20, and cox5a
Table 1
Genotypes and sources of S. cerevisiae strains
Strain Genotype Source
W303-1A a ade2-1 his3-1,15 leu2-3,112 trp1-1, ura3-1 a
W303-1B K ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 a
C261 K met6 cyc3 [7]
WC261 K ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 cyc3 C261UW303-1A
WC261-iCOX15 K ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 cyc3 trp1: :pGCOX15-3 this study
WC261vYAH1/ST1-iCOX15 K ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 cyc3 yah1: :URA3 trp1: :pGCOX15-3+pYAH1/
ST1
this study
WC261vYAH1/ST109-iCOX15 K ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 cyc3 yah1: :URA3 trp1: :pGCOX15-3+pYAH1/
ST109
this study
aW303vCOX11 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 cox11: :HIS3 [8]
aW303vCOX14 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 cox14: :HIS3 [9]
aW303vCOX15 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 cox15: :HIS3 [10]
aW303vCOX18 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 cox18: :URA3 [11]
aW303vCOX20 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 cox20: :URA3 [12]
W303vIMP2 K ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 imp2: :URA3 [5]
aW303vSCO1 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1sco1: :URA3 [13]
aW303vSHY1 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1shy1: :URA3 [14]
aW303vPET111 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1pet111: :HIS3 this study
aW303vPET117 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1pet117: :HIS3 this study
aW303vCOX15/eCOX10 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 cox15: :HIS3+pG19/T4 this study
W303-1A/eCOX10 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 + pG19/T4 this study
aW303vCOX14/eCOX10 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 cox14: :HIS3+pG19/T4 this study
aW303vCOX11/eCOX10 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 cox11: :his3+ pG19/T4 this study
W303vSCO1/eCOX10 K ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 sco1: :URA3+ pG19/T4 this study
aW303vIMP2/eCOX10 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 imp2: :URA3+ pG19/T4 this study
W303vIMP2vCOX15 K ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 imp2: :URA3 cox15: :HIS3 this study
W303vSCO1vCOX15 K ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 sco1: :URA3 cox15: :HIS3 this study
aW303vPET117vCOX15 a ade2-1 his3-1,15 leu2-3,112, trp1-1 ura3-1 pet117: :HIS3 cox15: :HIS3 this study
aWC261vCOX15 a ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 cyc3 cox15: :HIS3 this study
aR. Rothstein, Department of Human Genetics and Development, Columbia University.
The multicopy plasmids pG19/T4 and pYAH1/ST1, and the integrative plasmid pGCOX15-3 and have been described in [28], [4], and [5], re-
spectively.
Table 2
Heme A and heme O levels in COX mutants
Strain Gene Function Heme A/B Heme O/B Heme A/O
W303-1A ^ ^ 0.29 0.0037 V80
aW303vSCO1 SCO1 copper delivery to Cox2p 0.001 0.045 0.022
aW303vCOX10 COX10 heme:farnesyl transferase 0 0 ^
aW303vCOX11 COX11 copper delivery to Cox1p 0.001 0.076 0.013
aW303vCOX14 COX14 assembly of COX 0.005 0.1 0.05
aW303vCOX15 COX15 heme O hydroxylation 0 0.025 ^
aW303vCOX18 COX18 insertion of Cox2p 0.01 0.05 0.2
aW303vCOX20 COX20 chaperone of Cox2p 0.078 0.042 1.86
aW303vPET111 PET111 translation of Cox2p 0.006 0.07 0.086
aW303vPET117 PET117 assembly of COX 0.004 0.094 0.043
aW303vSHY1 SHY1 assembly of COX 0.04 0.003 13.3
aW303vIMP1 IMP1 processing of Cox2p 0.006 0.15 0.04
aW303vIMP2 IMP2 processing of Cox2p 0.002 0.17 0.011
WC261 CYC3 cytochrome c heme lyase 0.002 0.05 0.04
Mitochondrial hemes were extracted and separated by reverse phase chromatography as described in Section 2. The values reported in the table
are calculated from the areas under the peaks corresponding to heme A, B (protoheme) and heme O. Since the extinction coe⁄cient for each
heme at 400 nm is di¡erent, these values should not be interpreted to correspond to molar ratios.
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(not shown) mutants that retain 10^25% heme A. The heme A
is probably associated with the residual COX present in these
strains [25,26].
Since COX de¢cient mutants have low (6 10%) concentra-
tions of Cox1p, the heme-bearing component of the enzyme,
the decrease in heme A could be due to turnover of heme A
not bound to Cox1p. This explanation is incompatible with
the ability of some mutants to maintain high concentrations
of heme A, even when Cox1p is nearly completely absent.
CYC3 codes for the lyase that catalyzes a covalent linkage
of heme to apocytochrome c [27]. For reasons that are not
clear at present, mutants lacking cytochrome c, including cyc3
mutants, do not assemble COX [28]. Predictably, cyc3 mu-
tants, like all other COX assembly defective mutants, accu-
mulate heme O and have very low concentrations of heme A
(Table 2, Fig. 1). Heme A is substantially increased in cyc3
mutants overexpressing Cox15p (Fig. 1). The increase in heme
A is even more pronounced in cyc3 mutants overexpressing
both Cox15p and Yah1p encoded by YAH1 (Fig. 1). The
heme A in such strains is also detected spectrally in mitochon-
dria (Fig. 2A). Unlike cytochromes a and a3, which have K
absorption bands at 605 nm, the K absorption band of heme
A in the cyc3 transformant peaks at 595 nm, indicative of a
non-native environment. The almost complete absence of
Cox1p in the transformant (Fig. 2B) con¢rms that the heme
A cannot be associated with its usual protein partner. The
cyc3 mutant overexpressing Cox15p and Yah1p accumulates
a new compound (labeled X in Fig. 1). This peak is also seen
in other mutants transformed with COX15 and YAH1 but its
concentration is much lower. This compound has not been
identi¢ed but could be the hydroxylated intermediate.
The relatively high concentrations of heme A in cyc3 and in
other COX mutants transformed with COX15 and YAH1 [5]
argues against rapid turnover of heme as a plausible explan-
ation for its almost complete absence in such strains. The
presence of heme A in mutants lacking Cox1p also makes it
unlikely that heme A synthesis depends on an interaction of
heme O with this subunit. Instead, our data suggest that con-
version of heme O to heme A is coupled to some event or step
in COX assembly. The coordinate production of heme A and
COX could involve positive regulation of its synthesis by a
subunit/intermediate (e.g. Cox1p or holoenzyme) of the en-
zyme. The absence or reduced levels of this subunit/intermedi-
ate in mutants defective in COX assembly could account for
their repressed heme A synthesis. Alternatively, heme A pro-
duction could be negatively regulated by an assembly inter-
mediate. Increased concentrations of such an intermediate in
assembly-arrested mutants could also act to inhibit heme A
synthesis. Although less attractive, this explanation can also
account for the low concentration of heme A in the mutants.
The accumulation of heme O in most mutants (Table 2)
indicates that hydroxylation of heme O, catalyzed by
Cox15p, is the rate-limiting step in the pathway and is the
most likely target for either mode of regulation.
2.2. Mutations in COX15 repress heme O synthesis and have a
dominant e¡ect when combined with other mutations
The accumulation of heme O in COX mutants (Table 2)
indicates that this intermediate is stable. Based on the pro-
posed function of Cox15p in heme O hydroxylation [4,5]
cox15 mutants should have high concentrations of this
heme. The fact that they have very low levels of heme O
implies additional regulation of the pathway. To determine
if the cox15 phenotype is dominant, heme O was analyzed
in double mutants, in which the cox15 null allele was com-
bined with mutations in other COX-speci¢c genes. These as-
Fig. 1. Mitochondrial hemes in wild type yeast and in cyc3 mutants. Mitochondria were prepared from yeast grown in 2% rich galactose me-
dium. The following strains were analyzed: W303-1A (WT); WC261 (cyc3) a respiratory de¢cient strain with a point mutation in CYC3 ;
WC261-iCOX15 (cyc3 iCOX15), the cyc3 mutant with the GAL10^COX15 fusion gene integrated at trp1 ; WC261vYAH1/ST1-iCOX15 (cyc3
vyah1 iCOX15+pYAH1/ST1): a cyc3, yah1 double mutant containing chromosomally integrated GAL10^COX15 fusion gene and YAH1 on a
high copy episomal plasmid (pYAH1/ST1). Because Yah1p is an essential protein, the yah1 null allele allows selection of pYAH1/ST1. Total
hemes were extracted and analyzed on a reverse phase C18 column as described in Section 2. The peaks corresponding to heme B (B), heme A
(A), heme O (O), and a porphyrin compound (P) are marked. The peak labeled X has not been identi¢ed but could be the hydroxylated inter-
mediate. The ratios of heme A to heme B (A/B) were calculated from the areas under the peaks.
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says indicate that introduction of the cox15 mutation, in each
case, causes a reduction in heme O (Fig. 3). With the excep-
tion of the cox15, imp2 mutant, the heme O concentration of
the other double mutants was similar to that of the cox15
mutant. Introduction of the cox15 allele into the imp2 back-
ground, nonetheless, caused a two-fold decrease in heme O.
As a further test of Cox15p-dependent regulation of heme
O synthesis, we examined the e¡ect of overexpression of the
farnesyl transferase on heme O accumulation in a panel of
COX mutants. The mutants were transformed with pG19/
T4, a high copy plasmid containing COX10 [30]. All the
COX de¢cient strains, except the cox15 mutant have at least
two times more heme O when they harbor COX10 on a high
copy plasmid (Fig. 4). The failure of farnesyl transferase over-
expression to raise the heme O level in the cox15 mutant is
consistent with a Cox15p-dependent activation of the ¢rst step
in the heme A biosynthetic pathway.
The farnesyl transferase activity of Cox10p could require
the presence of Cox15p if the two proteins are part of a
complex. This explanation, however, is unlikely in view of
the identical sedimentation property of Cox15 extracted
from wild type and from a cox10 null mutant (data not
shown). The dependence of heme farnesylation on Cox15p,
therefore, is likely to involve some other mechanism such as
activation the farnesyl transferase by the hydroxylated prod-
uct.
Fig. 2. Spectra and steady state concentration of Cox1p in wild type and cyc3 mutants. A: Mitochondria were prepared from the respiratory
competent haploid strain W303-1A (WT), from the cytochrome c lyase mutant WC261 (cyc3), and from WC261vYAH1/ST109-iCOX15 (cyc3
vyah1 iCOX15+pYAH/ST109), a cyc3, yah1 double mutant with a chromosomally integrated copy of the GAL10^COX15 fusion and yah1 on
the high copy plasmid pGYAH1/ST109. The yah1 gene in pYAH/ST109 has two mutations (H108S and Y134C) that partially impair the activ-
ity of Yah1p (Barros, unpublished). Mutations in the corresponding residues of human Yah1p have been reported to a¡ect its interaction with
redox partners [29]. The reduced (dithionite) versus oxidized (ferricyanide) spectrum of the cyc3 mutant shows a reduction in absorbance at 550
nm due to the absence of cytochrome c but not c1. This strain also lacks the 605 nm K absorption band corresponding to cytochromes a and
a3. The spectrum of the cyc3, yah1 double mutant harboring the GAL10^COX15 fusion and pYAH/ST109 is identical to that of the cyc3 mu-
tant except for the appearance of a new band with a maximum at 595 nm. B: Western analysis of Cox1p. Mitochondria (20 Wg protein) from
the same strains used for the spectra shown in A were separated by SDS^PAGE on a 12% polyacrylamide gel. Following transfer to nitrocellu-
lose, the blot was probed with a monoclonal antibody against yeast Cox1p (arrow in margin).
Fig. 3. Ratios of heme O to heme B in single and double mutants.
Mitochondria were prepared from the following mutants grown in
rich galactose medium: aW303vSCO1 (vsco1), aW303vIMP2
(vimp2), WC261 (cyc3), aW303vPET117 (vpet117) and aW303v
COX15 (vcox15). Strains containing the same mutations combined
with the cox15 null allele were obtained by crosses of the single mu-
tants to W303vCOX15. Hemes were analyzed in the single mutants
(clear bars) and double mutants (¢lled bars) as described in Table
2.
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The heme A biosynthetic pathway may be subject to still
other regulatory in£uences. For example, deletion of mito-
chondrial DNA in the imp2 mutant elicits a four-fold decrease
in the steady state concentration of heme O (compare Table 2
and Fig. 4). The present studies point to heme O hydroxyla-
tion, catalyzed by Cox15p, as an important regulatory step.
As indicated in Fig. 5, activation of heme A synthesis by
downstream assembly events may be the mechanism for coor-
dinating the rate of heme A synthesis with its utilization for
COX maturation.
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Fig. 5. Proposed regulation of heme A synthesis. Hydroxylation of
heme O is positively regulated by a downstream assembly intermedi-
ate or subunit of COX (arrows). Farnesylation of heme B is also
shown to be positively regulated (arrow) either by Cox15p or the
hydroxylated intermediate.
Fig. 4. Ratios of heme O to heme B in mutants overexpressing
heme :farnesyl transferase. Mitochondria were prepared from a b0
derivative of the wild type strain W303-1A (W303 b0) and from the
COX de¢cient mutants aW303vIMP2b0 (vimp2 b0), aW303vCOX11
(vcox11), aW303vCOX14 (vcox14), aW303vSCO1 (vsco1),
aW303vCOX15 (vcox15). The mutants were also transformed with
COX10 on a high copy plasmid (pG19/T4). Hemes were analyzed in
the mutants (clear bars) and transformants (¢lled bars) as described
in the legend of Table 2.
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